ALFA Filings
Every announcement, straight from the exchange
Every Sudarshan Pharma Industries merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
Sudarshan Pharma Industries Ltd will acquire 3,000 shares, representing a 30% stake, in Sudarshan Maven Pharma Private Limited. This strategic acquisition will make the entity a wholly-owned subsidiary.
Sudarshan Pharma incorporated a wholly-owned US subsidiary, Sudarshan Industries Inc. This expands its international footprint and customer base in the USA.